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Background: Autism spectrum disorder (ASD) is defined by standardized criteria of qualitative impairments in social
interaction, qualitative impairments in communication, and restricted and stereotyped patterns of behavior,
interests, and activities. A significant number of children diagnosed with ASD suffer a loss of previously-acquired
skills, which is suggestive of neurodegeneration or a type of progressive encephalopathy with an etiological
pathogenic basis occurring after birth. To date, the etiology of ASD remains under debate, however, many studies
suggest toxicity, especially from mercury (Hg), in individuals diagnosed with an ASD. The present study evaluated
concerns about the toxic effects of organic-Hg exposure from Thimerosal (49.55% Hg by weight) in childhood
vaccines by conducting a two-phased (hypothesis generating/hypothesis testing) study with documented exposure
to varying levels of Thimerosal from vaccinations.
Methods: A hypothesis generating cohort study was undertaken to evaluate the relationship between exposure to
organic-Hg from a Thimerosal-containing Diphtheria-Tetanus-acellular-Pertussis (DTaP) vaccine in comparison to a
Thimerosal-free DTaP vaccine administered, from 1998 through 2000, for the risk of ASD as reported in the Vaccine
Adverse Event Reporting System (VAERS) database (phase I). A hypothesis testing case–control study was
undertaken to evaluate the relationship between organic-Hg exposure from Thimerosal-containing hepatitis B
vaccines administered at specific intervals in the first six months of life among cases diagnosed with an ASD and
controls born between 1991 through 1999 in the Vaccine Safety Datalink (VSD) database (phase II).
Results: In phase I, it was observed that there was a significantly increased risk ratio for the incidence of ASD
reported following the Thimerosal-containing DTaP vaccine in comparison to the Thimerosal-free DTaP vaccine. In
phase II, it was observed that cases diagnosed with an ASD were significantly more likely than controls to receive
increased organic-Hg from Thimerosal-containing hepatitis B vaccine administered within the first, second, and sixth
month of life.
Conclusions: Routine childhood vaccination is an important public health tool to reduce the morbidity and
mortality associated with infectious diseases, but the present study provides new epidemiological evidence
supporting an association between increasing organic-Hg exposure from Thimerosal-containing childhood vaccines
and the subsequent risk of an ASD diagnosis.
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Over the past two decades, the prevalence of individuals
diagnosed with autism spectrum disorder (ASD) has
risen dramatically [1], and currently at least 1 in 88 chil-
dren are diagnosed with ASD in the US [2]. ASD is de-
fined by standardized criteria of qualitative impairments
in social interaction, qualitative impairments in commu-
nication, and restricted and stereotyped patterns of be-
havior, interests, and activities [3]. Although these core
features define an ASD, recent investigations have de-
scribed many health, physical, or behavioral co-morbid
conditions consistently associated with an ASD such as
gastrointestinal disturbances, incontinence, sleep prob-
lems, eating disorders, behavioral problems, and sensory
processing issues [4].
In further considering the initial clinical presentation
of ASD, a significant number of children diagnosed with
ASD suffer a loss of previously-acquired skills between 6
and 18 months of age with an estimated incidence of re-
gression among individuals diagnosed with ASDs ran-
ging from 15% to more than 62% of all cases [5]. The
importance of postnatal loss of neurological function in
those diagnosed with an ASD between 6 and 18 months
of age, as observed in affected children who have
regressed, is this phenomena is suggestive of neurode-
generation or a type of progressive encephalopathy with
an etiological pathogenic basis occurring after birth [5].
To date, the etiology of ASD remains under debate.
However, many studies suggest toxicity in individuals di-
agnosed with an ASD [6]. More specifically, recent evi-
dence suggests that mercury (Hg) may be either a causal
factor in or contributory to the brain pathology in ASD,
possibly working synergistically with other toxic com-
pounds or pathogens to produce the abnormal brain
pathology observed in those diagnosed with an ASD [7].
Hg is a heavy metal that is widespread and persistent
in the environment, and infants in the US are exposed
to significant levels of environmental Hg through the air,
water, and breast milk [8]. In addition to environmental
Hg exposure and maternal exposures from the mother’s
Hg body burden, dietary intakes, and Hg-containing
pharmaceuticals administered to the mother while the
child is developing in utero, and injected organic-Hg
from Thimerosal-containing childhood vaccines that have
been and, in many countries, remain a significant source
of Hg exposure for many infants during the first six
months of life.
Thimerosal is an organic-Hg compound (49.55% Hg
weight) added to vaccines as a preservative, typically at
concentrations from 0.005% to 0.01% (12.5 μg Hg or
25 μg Hg per 0.5 mL vaccine dose) [9]. Thimerosal is
known to rapidly dissociate into ethyl-Hg chloride,
ethyl-Hg hydroxide, and sodium thiosalicylate in saline
solutions. As a result of adherence to the recommendedroutine childhood vaccination schedule in the US during
the 1990s infants may have been exposed to bolus doses
of Hg nominally ranging from 12.5 μg Hg to 62.5 μg Hg
that collectively added up to nominally 200 μg Hg from
Thimerosal-containing childhood vaccines during the
first six months of life (3 Diphtheria-Tetanus-Pertussis
vaccines with 25 μg Hg per dose + 3 Haemophilus influ-
enzae type B vaccines with 25 μg Hg per dose + 3 hepa-
titis B vaccines with 12.5 μg Hg per dose + 1 influenza
vaccine with 12.5 μg Hg per dose, > 50% of all Hg ex-
posure when considering environmental sources of Hg).
This dosing pattern continues unabated in many devel-
oping nations to the present day. Moreover, despite a
call for the removal of Thimerosal from all vaccines in
the United States on July 7, 1999 by the American Acad-
emy of Pediatrics and United States Public Health Ser-
vice [10], many children in the US continue to receive
significant doses of Hg from the routinely recommended
administration of Thimerosal-containing influenza vac-
cines (where more than 50% of all doses of influenza
vaccine continue to contain 0.01% Thimerosal) to preg-
nant women, infants, and young children [9].
The purpose of the present study was to evaluate con-
cerns about the toxic effects of organic-Hg exposure
from Thimerosal in childhood vaccines by conducting a
two-phased study with documented exposure to varying
levels of Thimerosal from vaccinations. In the first
phase, a hypothesis generating study was undertaken to
evaluate the relationship between exposure to organic-
Hg from a Thimerosal-containing Diphtheria-Tetanus-
acellular-Pertussis (DTaP) vaccine in comparison to a
Thimerosal-free DTaP vaccine for the risk of ASD in the
Vaccine Adverse Event Reporting System (VAERS) data-
base (phase I). In the second phase, a hypothesis testing
study was undertaken to evaluate the relationship be-
tween organic-Hg exposure from Thimerosal-containing
hepatitis B vaccines administered at specific intervals
and the risk of ASD in the Vaccine Safety Datalink
(VSD) database (phase II).
Methods
Phase I (hypothesis generating) - VAERS database
The VAERS is an epidemiological database that has been
maintained jointly by the US Centers for Disease Con-
trol and Prevention (CDC) and US Food and Drug Ad-
ministration (FDA) since 1990 as a surveillance tool to
evaluate vaccine safety. Specific adverse events following
vaccination are required to be reported to this database
as mandated by law, but other adverse events that occur
following vaccine administration are passively reported
to VAERS. The VAERS Working Group of the CDC has
previously acknowledged that less than 5% of the total
adverse events reported to VAERS are reported by par-
ents. Specific serious adverse events and deaths reported
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VAERS Working Group of the CDC and the FDA have
repeatedly analyzed and published epidemiologic studies
based upon VAERS [11,12].
The VAERS Working Group notes that VAERS is simple
to use, flexible by design, and the data are available in a
timely fashion, but it also warns that the potential limita-
tions may include systematic error due to underreporting,
erroneous reporting, frequent multiple exposures, multiple
outcomes and lack of precise denominators. In addition,
when evaluating data from VAERS, it is important to note
that, for any reported event, no cause and effect relation-
ship has been established. VAERS is interested in all poten-
tial associations between vaccines and adverse events.
Therefore, VAERS collects information on any adverse
event following vaccination, be it coincidental or truly
caused by a vaccine [11,12].
An analysis of the VAERS updated through June 12, 2013
was undertaken using the CDC Wonder online computer
interface (http://wonder.cdc.gov/vaers.html). This portal
provides a direct method for independent investigators to
rapidly analyze up-to-date data in VAERS.
Determining the population at risk
The population at risk included infants receiving either
Thimerosal-containing DTaP vaccines manufactured by
Pfizer\Wyeth-Lederle Laboratories (ACEL-IMMUNE™) or
Thimerosal-free DTaP vaccines manufactured by GlaxoS-
mithKline (INFANRIX™), both of which were administered
in the United States from 1998 through 2000.
Determining outcomes
The VAERS was searched for ASD adverse event reports
with outcome symptoms of autism (VAERS code:
10003805) and autism spectrum disorder (VAERS code:
10063844) among those with a specified state of residency
in the United States. Among the adverse event reports iden-
tified, only those associated with Thimerosal-containing
DTaP vaccines manufactured by Pfizer\Wyeth-Lederle
Laboratories (VAERS code: 234) or Thimerosal-free DTaP
vaccine doses manufactured by GlaxoSmithKline (VAERS
code: 286) administered in the United States from 1998
through 2000 were examined in the present study. Overall,
it was determined that there were a total of 38 ASD adverse
events reported to VAERS following Thimerosal-containing
DTaP vaccine doses manufactured by Pfizer\Wyeth-Lederle
Laboratories and a total of 17 ASD adverse events reported
to VAERS following Thimerosal-free DTaP vaccine doses
manufactured by GlaxoSmithKline. These numbers were
used as the numerators in phase I.
Determining exposure
The Biologics Surveillance Summaries (BSS) of the CDC,
which are broken down by vaccine manufacturer, were usedto determine the net number of doses of vaccine distrib-
uted (this number subtracts the number of doses returned
to the manufacturer from the total number distributed)
(personal communication from Lisa Galloway of the CDC
on May 23, 2002). The applicable BSS reported a total of
14,794,210 net number of doses of the Thimerosal-free
DTaP vaccine were distributed from 1998 through 2000
and a total of 16,335,650 net number of doses of the
Thimerosal-containing DTaP vaccine were distributed from
1998 through 2000. These numbers were used as the
denominators in phase I.
Statistical analyses
The Fisher’s exact test contained in the StatsDirect (ver-
sion 2.7.8) statistical software package was utilized for
statistical analyses, and a two-sided p-value < 0.05 was
considered to be statistically significant. A comparison
of the frequency of ASD adverse events reported to
VAERS per the total net number of doses for each vac-
cine type was completed. The null hypothesis was that,
regardless of Thimerosal content of the vaccines under
study, a similar frequency would be observed for ASD
adverse events reported to VAERS per the total net
number of doses for each vaccine type.
Phase II (hypothesis testing) VSD database
The study protocol employed was approved by the CDC,
the Institutional Review Board (IRB) of Kaiser Perma-
nente North-West (KPNW), and the IRB of Kaiser
Permanente Northern California (KPNC). The data were
analyzed at the secure Research Data Center of the
National Center for Health Statistics in Hyattsville, MD.
The views expressed in this study do not necessarily
reflect those of the CDC or those of Kaiser Permanente.
Determining the population at risk
A cohort of infants enrolled in the VSD project (updated
through the end of 2000) from KPNW, Kaiser Perma-
nente Colorado (KPC), and KPNC were examined using
SAS® software. The VSD project was created in 1991 by
the National Immunization Program (NIP) of the CDC
and VSD methods were previously described [13-15].
The project links medical event information, specific
vaccine history, and selected demographic information
from the computerized databases of several HMOs. The
cohort examined was comprised of individuals with
non-missing date of birth, non-missing gender, and were
HMO enrolled from their date of birth.
Determining cases
The outcome files (inpatient and outpatient diagnoses)
from this population were then reviewed to find the first
instance of International Classification of Disease, 9th
revision (ICD-9) diagnosed ASD (ICD-9 code: 299.00). If
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child, only the first instance was counted. In addition, to
ensure the potential for an association between exposure
and outcome, only individuals diagnosed with an ASD
following administration of all the vaccines under study
were included in the present analyses as cases.
A total of 307 cases diagnosed with ASD (males = 249,
females = 58, male/female ratio = 4.3:1) born between
1991 through 1999 were identified. These individuals
diagnosed with ASD were evaluated to determine their
mean age of initial diagnosis of ASD and the standard
deviation of mean age of initial diagnosis of ASD (4.2 ±
1.54 years-old).
Determining controls
In order to identify controls without an ASD diagnosis
who would have only a minimal chance of receiving
such a diagnosis, controls had to have been continuously
enrolled from birth for at least 7.29 years (mean age of
initial diagnosis of ASD + 2× standard deviation of mean
age of initial diagnosis of ASD). Applying this follow-up
criterion yielded a total of 25,632 controls without an
ASD diagnosis (males = 13,110, females = 12,522, male/
female ratio = 1.05) born between 1991 through 1993.
Hepatitis B vaccine exposure
The vaccine file for cases and controls was then
reviewed to determine the exact dates of hepatitis B vac-
cine administration. Those cases and controls receiving
no doses of hepatitis B vaccine were also included in the
present study. Overall among the cases and controls, Hg
exposure was assigned as 12.5 μg organic-Hg per dose
for those receiving a pediatric hepatitis B vaccine or 0 μg
organic-Hg per dose for those receiving combined Hae-
mophilus influenzae type b (Hib)-hepatitis B vaccine or
for those receiving none of the aforementioned vaccines.
Statistical analyses
The Fisher’s exact test contained in the SAS® software
was utilized for statistical analyses, and a two-sided p-
value < 0.05 was considered statistically significant. In
the first case–control experimental group (Experiment
I), the data was examined to determine the frequency of
exposure to 12.5 μg organic-Hg from a Thimerosal-
containing hepatitis B vaccine in the first month of life
in comparison to the frequency to 0 μg organic-Hg from
Thimerosal-containing hepatitis B vaccine in the first
month of life among cases and controls. In the second
case–control experimental group (Experiment II), the
data was examined to determine the frequency receiving
two Thimerosal-containing hepatitis B vaccines within
the first two months of life or a total of 25 μg organic-
Hg in comparison to the frequency receiving 0 μg
organic-Hg from Thimerosal-containing hepatitis Bvaccines in the first two months of life among cases and
controls. In the third case–control experimental group
(Experiment III), the data was examined to determine
the frequency of receiving three Thimerosal-containing
hepatitis B vaccines within the first six months of life or
a total of 37.5 μg organic-Hg in comparison to the fre-
quency of receiving 0 μg organic-Hg in the first sixth
months of life from Thimerosal-containing hepatitis B
vaccines among cases and controls. The overall null hy-
potheses for each of the case–control experimental
groups examined was that there would be no difference
in the frequency of exposure to organic-Hg doses from




Table 1 shows the relationship between ASD adverse events
reported to VAERS following Thimerosal-containing DTaP
vaccine administration in comparison to Thimerosal-free
DTaP vaccine. It was observed that there was a 2.02-fold
significantly (p < 0.02) increased risk ratio for the incidence
of ASD reported following the Thimerosal-containing DTaP
vaccine in comparison to the Thimerosal-free DTaP
vaccine.
Phase II
Table 2 displays the relationship between cases and con-
trols being administered increasing doses of organic-Hg
from Thimerosal-containing hepatitis B vaccines at sev-
eral specific points within the first six months of life. It
was observed that cases were significantly more likely
(odds ratio = 2.18, p < 0.00001) than controls to receive
12.5 μg organic-Hg from Thimerosal-containing hepa-
titis B vaccine in comparison to 0 μg organic-Hg from
Thimerosal-containing hepatitis B vaccine within the
first month of life. It was also observed that cases were
significantly more likely (odds ratio = 2.11, p < 0.0001)
than controls to receive 25 μg organic-Hg from
Thimerosal-containing hepatitis B vaccines in compari-
son to 0 μg organic-Hg from Thimerosal-containing
hepatitis B vaccines within the first two months of life.
Finally, cases were significantly more likely (odds ratio =
3.39, p < 0.001) than controls to receive 37.5 μg organic-
Hg from Thimerosal-containing hepatitis B vaccines in
comparison to 0 μg organic-Hg from Thimerosal-
containing hepatitis B vaccines within the first six
months of life.
Discussion
The present study evaluated the potential relationship be-
tween organic-Hg exposure from Thimerosal-containing
childhood vaccines and ASD using a two-phase study de-
sign. In the first phase, the VAERS database was analyzed
Table 1 A summary of Thimerosal-containing DTaP vaccine administration in comparison to Thimerosal-free DTaP
vaccine as a risk factor for ASD adverse event reports in the VAERS
Group examined Number autism/Autism spectrum
disorder events
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ciation between increasing organic-Hg exposure from
Thimerosal-containing DTaP vaccine administration in
comparison to Thimerosal-free DTaP vaccine for the risk of
ASD. In the second phase, the VSD database was analyzed
for hypothesis testing, and it revealed that those cases diag-
nosed with an ASD were at significantly greater risk of ex-
posure to increasing doses of organic-Hg from Thimerosal-
containing hepatitis B vaccines administered at three spe-
cific intervals within the first six months of life in compari-
son to controls.
The overall two-phased epidemiological method to
evaluate vaccine safety using the VAERS for hypothesis
generation (phase I) and the VSD for hypothesis testing
(phase II) was previously described by investigators from
the CDC and the FDA [16-18]. Specifically, these investi-
gators described that products, such as vaccines, which
are intended for healthy people, must be held to a high
standard of safety assurance. However, the study of vac-
cine risks is more complex than for therapeutic productsTable 2 A summary of organic-mercury exposure from Thime
among ASD cases and controls in the VSD database




12.5 μg organic-mercury within 1st
month
155 (50.49)




25 μg organic-mercury within first
2 months
154 (50.49)




37.5 μg organic-mercury within first
6 months
30 (76.92)
0 μg organic-mercury within first
6 months
9 (23.08)because the exposure is virtually universal for many
vaccines, ensuring the chance occurrence of many ad-
verse outcomes in temporal association with vaccines.
As a result, these investigators described a two-phased
approach by first identifying vaccine safety risks through re-
ports to VAERS (hypothesis generating), and then using the
VSD, a consortium of managed care organization, to more
rigorously evaluate vaccine-associated risks (hypothesis
testing).
It is interesting to consider the specific methods
employed to evaluate the potential relationship between
organic-Hg exposure from Thimerosal-containing child-
hood vaccines and the risk of ASD in each of the two
phases of the present study. Specifically, in phase I, dif-
ferences in organic-Hg content were evaluated based
upon the differences in Thimerosal content of two dif-
ferent DTaP vaccines manufactured by different com-
panies (i.e., one used Thimerosal as a preservative and
the other used 2-phenoxyethanol). Other than the differ-
ence in organic-Hg content based upon vaccinerosal-containing hepatitis B vaccine administration






2.18 (1.74–2.73) < 0.00001
17,471 (68.16)
8,172 (32.55)
2.11 (1.68–2.64) < 0.0001
16,935 (67.45)
1,073 (49.54)
3.39 (1.60–7.18) < 0.001
1,093 (50.46)
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mended for administration to US infants in the same
vaccine schedule at 2, 4, and 6 months of age [19].
Specifically, in phase II, differences in cumulative
doses of organic-Hg received at specific intervals during
the infant period were evaluated based upon the wide-
ranging recommendations for routine hepatitis B vaccine
administration. In 1991, the Advisory Committee on
Immunization Practices (ACIP) recommended that in-
fants should receive their hepatitis B vaccine doses as
follows: first dose between birth and 2 months of age,
second dose between 1 and 4 months of age, and third
dose between 6 and 18 months of age [20].
Importantly, all told, it is apparent that the differences
in organic-Hg exposures observed in both phases of the
present study were not the result of a small group of
children receiving anomalous exposures to vaccines. In-
stead, in phase I, these differences were a function of
vaccine composition by vaccine manufacturer. Alterna-
tively, phase II assessed varying levels of organic-Hg ex-
posure which resulted from the varying windows
recommended for administration of hepatitis B vaccines
during the first year of life.
The results observed in the present study also appear to
offer important potential biological mechanistic insights into
the relationship between the timing and cumulative effects
of organic-Hg exposure from Thimerosal-containing vac-
cines and the risk of receiving a diagnosis of ASD. For
example, the effects of later additional organic-Hg exposure
from administration of a second or third Thimerosal-
containing hepatitis B vaccine did not increase the risk of re-
ceiving a diagnosis of ASD in a dose-proportional manner
(i.e., odds ratio for second dose of Thimerosal-containing
hepatitis B vaccine = 4 and odds ratio for third dose of
Thimerosal-containing hepatitis B vaccine = 6). Instead, the
odds ratio of receiving an ASD diagnosis after receiving two
doses of Thimerosal-containing hepatitis B vaccine (25 μg
organic-Hg) by two months of age was similar to the of re-
ceiving one dose of Thimerosal-containing hepatitis (12.5 μg
organic-Hg) by one month of age. The odds ratio for receiv-
ing an ASD diagnosis after three doses of Thimerosal-
containing hepatitis B vaccine (37.5 μg organic-Hg) was
increased relative to those children receiving one or two
doses of Thimerosal-containing hepatitis B vaccine, but the
increase observed was significantly below what which would
be expected from a cumulative perspective without consid-
ering the variable of timing of administration. Our observa-
tion of odds ratio being modified by time of exposure is
consistent with previous observations regarding other cases
of Hg intoxication, in which early exposure is associated
with more significant adverse effects (i.e., Hg intoxication
susceptibility: fetuses > infants > children > adults) [21].
In addition, the results observed in the present study sup-
port the hypothesis that a significant number of childrendiagnosed with an ASD experience neurodegeneration or a
type of progressive encephalopathy with an etiological
pathogenic basis occurring after birth. This is the case be-
cause the source of exposure examined in the present study
was from Thimerosal-containing childhood vaccines ad-
ministered between birth and 6 months of age, and a sig-
nificant number of children diagnosed with an ASD have
been reported to suffer a loss of previously-acquired skills
between 6 and 18 months of age [5]. Because those exposed
to Thimerosal-containing vaccines have a statistically sig-
nificant increased risk of being diagnosed with an ASD, and
because administration of Thimerosal-containing vaccines
examined in this study was administered between birth and
6 months of age, it is valid to suggest that a significant
number of individuals examined in this study who were di-
agnosed with an ASD suffered neurodegeneration or a type
of progressive encephalopathy for which the etiological
pathogenic basis was exposure to organic-Hg from Thimer-
osal administered as a vaccine component.
Importantly, many recent studies support the biologically
plausible role of organic-Hg exposure from Thimerosal-
containing vaccines in the pathogenesis of ASD [9]. Investi-
gators have examined the distribution of organic-Hg fol-
lowing administration of Thimerosal to animals and
infants. For example, administering Thimerosal mimicking
the US vaccine schedule of the 1990s to infant monkeys, re-
searchers found that significant levels of Hg were present in
the brain (about 40–50 parts-per-billion), and a significant
fraction of the Hg was present as inorganic-Hg (about 16
parts-per-billion) that was observed to not significantly de-
cline 120 days following the last dose of Thimerosal [22].
Other investigators undertook further evaluations of the
speciation of Hg present in rat tissues following administra-
tion of Thimerosal [23]. Interestingly, these researchers ob-
served that administration of Thimerosal resulted in
significant brain levels of Hg with 63% present in the form
of inorganic-Hg, 13.5% as ethyl-Hg, and, unexpectedly,
23.7% as methyl-Hg.
In addition, investigators observed that Thimerosal-
containing vaccine administration to human infants
significantly increased the vaccinated infants’ blood
Hg levels (with some infants having total blood Hg
levels in excess of the safety limits established by the
US Environmental Protection Agency) and also sig-
nificantly increased the vaccinated infants’ hair ethyl-
Hg levels (with some infants having total hair Hg
levels in excess of the safety limits established by the
US Environmental Protection Agency of 1 part-per-
million) [9]. Finally, in further research on the distri-
bution of Hg species within the body, investigators
recently demonstrated that ethyl-Hg is actively trans-
ported across neuronal cellular membranes to the
same degree as methyl-Hg, by the L-type neutral
amino acid carrier transport (LAT) system [24].
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cause it can induce cellular damage consistent with the
neuronal damage observed in the brains of individuals
diagnosed with ASD, and this damage is dependent
upon thiol availability, especially glutathione, in that in-
adequate thiol availability results in significantly greater
cellular damage from Hg [7,25]. Many previous studies
reveal children diagnosed with ASD have limited thiol
availability and decreased glutathione reserve capacity,
deficits which make them more susceptible to the toxic
effects of Hg exposure from administration of
Thimerosal-containing vaccines [9].
Studies have also evaluated the potential for organic-
Hg exposure from Thimerosal-containing vaccine ad-
ministration to induce ASD pathology or clinical symp-
toms in animal model systems. These studies have
yielded significant pathology or clinical symptoms in
mice, rats, hamsters, and monkeys that are consistent
with those observed in ASD following exposure to
Thimerosal-containing vaccines mimicking the 1990s US
routine childhood vaccination schedule [9].
The results observed in the present study are also sup-
ported by a number of previous epidemiological studies
finding an association between organic-Hg exposure from
Thimerosal-containing vaccines and ASD, using several
epidemiological methods in various databases. For example,
Young et al., using an ecological study design, evaluated the
relationship between the birth cohort prevalence of specific
neurodevelopmental disorder and birth cohort exposures
to Hg from Thimerosal-containing childhood vaccines in
the VSD [26]. Consistent with the results observed in the
present study, it was seen that infants receiving an add-
itional 100 μg organic-Hg from Thimerosal-containing
childhood vaccines from birth to 7 months of age, had a
significantly increased risk ratio of 2.87 for ASD, and in-
fants receiving an additional 100 μg organic-Hg from
Thimerosal-containing childhood vaccines from birth to
13 months of age, had a significantly increased risk ratio of
2.62 for ASD.
As another example, Gallagher and Goodman evalu-
ated the relationship between administration of
Thimerosal-containing hepatitis B vaccine administra-
tion and the subsequent risk of individual being diag-
nosed with an ASD, based upon assessment of the
National Health Interview Survey (NHIS) 1997–2002
data sets [27]. They reported that boys diagnosed with
an ASD in comparison to controls had a 3-fold signifi-
cantly greater odds ratio for receiving a Thimerosal-
containing hepatitis B vaccine during the first month of
life.
Previously, Geier and Geier reported on the results of a
meta-analysis using statistical modeling to evaluate the rela-
tionship between exposure increased Hg doses from
Thimerosal-containing vaccines and neurodevelopmentaldisorder adverse event reports in VAERS [28]. They re-
ported that there was a 1.6-fold significantly increased risk
of ASD adverse event reports submitted to VAERS follow-
ing additional doses of organic-Hg from Thimerosal-
containing vaccine administration.
The results of the present study differ from several
other cohort studies that failed to find an association be-
tween ASD and organic-Hg exposure from Thimerosal-
containing childhood vaccines [29-31]. This may have
occurred, in part, because other studies examined co-
horts with significantly different childhood vaccine
schedules and with different diagnostic criteria for out-
comes. This difference may have also occurred because
these other studies employed different epidemiological
methods, especially with respect to the issue of follow-
up period for individuals in the cohorts examined. The
method used to measure follow-up period for individuals
is a critical issue in all studies examining the relationship
between exposures and the subsequent risk of an ASD
diagnosis. This is the case because the risk of an individ-
ual being diagnosed with an ASD is not uniform
throughout his/her lifetime. As observed in the present
study, the initial mean age for an ASD diagnosis was
4.2 years-old, and the standard deviation of mean age of
the initial diagnosis of ASD was 1.54 years-old. There-
fore, any follow-up method that fails to consider the lag-
time between birth and age of initial ASD diagnosis will
likely not be able to observe the true relationship be-
tween exposure and the subsequent risk of an ASD
diagnosis.
This type of concern is apparent with respect to the
study published by Hviid et al. [29]. These investigators
reported on a population-based cohort study of all chil-
dren born in Denmark from January 1, 1990, until De-
cember 31, 1996 comparing children vaccinated with a
Thimerosal-containing vaccine formulation (early years
of the study) with children vaccinated with a
Thimerosal-free formulation (latter years of the study) of
the same vaccine. In order to evaluate years of follow-up
for individuals in the study, these investigators described
them in terms of person-years. As a result, these investi-
gators assumed equality of person-years of contribution
to the study regardless the age of the individual, despite
observing a similar mean age of an ASD diagnosis (4.7 ±
1.7 years-old) as the present study. The consequence in
the Hviid et al. [29] study was that an out-of-proportion
number of person-years of follow-up was observed for
the older children who had received Thimerosal-
containing vaccine formulation in comparison to the
younger children vaccinated with a Thimerosal-free vac-
cine formulation, rendering the results of the study un-
interpretable. Similar limitations apply to the cohort
studies published by Andrew et al. [30] (median age of
initial ASD diagnosis = 4.4 years-old) and Verstraeten
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A = 49 months [4.08 years] and HMO B = 44 months
[3.67 years]), which used hazard models (i.e., models
which presume a constant relative hazard of ASD diag-
nosis over time) to evaluate follow-up of individuals in
their respective examinations of the relationship between
Thimerosal-containing vaccine exposures and the subse-
quent risk of an ASD diagnosis.
In order to further reveal the importance of follow-up
period, the following example is informative. In the afore-
mentioned Verstraeten et al. [31] study, the investigators
examined aVSD dataset that shared significant overlap with
the one examined in the present study. Verstraeten et al.
[31] observed a risk ratio = 1.16 (95% confidence interval =
0.78-1.71) for ASD diagnosed among infants receiving
12.5 μg organic-Hg exposure from Thimerosal-containing
vaccines administered in the first month of life. This obser-
vation is in contrast to the odds ratio = 2.18 (95% confi-
dence interval = 1.74-2.73) observed in the present study
when comparing cases to controls for receiving 12.5 μg
organic-Hg exposure from Thimerosal-containing hepatitis
B vaccine in comparison to receiving 0 organic-Hg expos-
ure from Thimerosal-containing hepatitis vaccine adminis-
tered in the first month of life. A further analysis of the
dataset examined in the present study, using reduced
lengths of continuous follow-up among controls presumed
to be without an ASD diagnosis, revealed that if the length
of continuous follow-up criteria was reduced to the mean
age of initial ASD diagnosis + standard deviation of initial
ASD diagnosis (5.7 years), the odds ratio = 1.69 (95% confi-
dence interval = 1.35-2.12). Further, if the length of continu-
ous follow-up criteria was reduced further among controls
to only the mean age of initial ASD diagnosis (4.2 years),
the odds ratio = 1.47 (95% confidence interval = 1.18-1.85).
Finally, if the length of continuous follow-up criteria was
reduced even further among controls to only the mean age
of initial ASD diagnosis - standard deviation of initial ASD
diagnosis (2.7 years), the odds ratio = 1.21 (95% confidence
interval = 0.97-1.51), a value that, considering the confi-
dence intervals, is consistent with the risk ratio = 1.16 (95%
confidence interval = 0.78-1.71) observed in the Verstraeten
et al. [31] study. Although the aforementioned odds ratios
are still statistically significant (except for the last analysis
requiring continuous follow-up criteria among controls to
only the mean age of ASD diagnosis - standard deviation),
the effect becomes less pronounced in each instance as in-
creasing levels of ambiguity of diagnosis are introduced
among controls due to the lack of appropriate follow-up.
Strengths/limitations
A strength of the present study involved examination of
two separate cohorts of children from two separate data-
bases (i.e., VAERS and VSD). The observations made in
VAERS were based upon retrospective assessment ofpassively reported adverse events. In contrast, the VSD ob-
servations were made based upon retrospective assessment
of prospectively collected medical records of patients en-
rolled in various HMOs. Despite these intrinsic differences
in data-collection methods between the two databases, in
both databases organic-Hg exposure from Thimerosal-
containing vaccine administration was consistently associ-
ated with a subsequent diagnosis of an ASD.
The study design used to evaluate the relationship be-
tween exposure and outcome was another significant
strength of the present study. In phase I of the study, ad-
verse event reports in VAERS were analyzed. The
method employed to examine VAERS ensured that the
exposures to the various types of vaccines studied oc-
curred prior to the outcomes described in the adverse
event reports, since those reporting the subsequent ad-
verse outcomes in association with the vaccines listed on
the adverse event reports. In phase II, cases had to be
enrolled from birth and were required to be continu-
ously enrolled until a medical diagnosis of an ASD was
made and controls had to be enrolled from birth for a
sufficient time period to ensure that there was a very
small chance that, during additional follow-up, any of
the controls would be medically diagnosed with an ASD.
As a result, any factors associated with enrollment (i.e.,
adjustment for potential independent variables between
cases and controls were not necessary because enroll-
ment was from birth) or healthcare-seeking behavior
(i.e., adjustment for potential access/availability of
healthcare was continuous among cases and controls)
were minimized.
For cases diagnosed with an ASD, it was possible to
mathematically evaluate the mean and standard devi-
ation of age for initial ASD diagnoses within the VSD.
From this information, it was possible to estimate how
many additional potential diagnoses of ASD were
missed. It was decided, a priori, to ensure adequate
amounts of data for our analyses, that controls had to be
continuously enrolled in the VSD from birth until they
were at least 7.29 years-old (mean age of initial diagnosis
of ASD + 2× standard deviation of mean age of initial
diagnosis of ASD). Based on the data for age of initial
diagnosis for ASD, this was a sufficient period to ensure
that, with further follow-up, those controls without an
ASD would probably not receive an ASD diagnoses in
the VSD (mathematically there is a < 2.5% chance of
these individuals being diagnosed with an ASD with
additional follow-up time beyond 7.29 years). In
addition, cases diagnosed with an ASD were specifically
evaluated to ensure that only those cases diagnosed with
an ASD following vaccine administration were consid-
ered in the present analyses.
Another strength of the study was that the VSD and
VAERS data were collected independently of the study
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analyzed, in particular, were collected as part of the rou-
tine healthcare individuals received as part of the partici-
pation with their respective HMOs, and as such, the
healthcare providers in no way were thinking about the
potential association between vaccine exposures and po-
tential health outcomes.
However, the results of the present study may have a
number of potential limitations. It is possible the results ob-
served may have occurred from unknown biases or co-
founders present in the datasets examined. This seems
unlikely because other control outcomes (i.e. outcomes that
are not biologically plausibly linked to postnatal organic-Hg
exposure from Thimerosal-containing vaccines) were ex-
amined, such as a diagnosis of congenital anomalies (ICD-9
code: 759.9) in the VSD database, using the same method-
ology employed for ASD. No similar patterns of significant
associations were observed as that found for organic-Hg ex-
posure from Thimerosal-containing hepatitis B vaccine ad-
ministration and the subsequent risk of ASD diagnosis. For
example, exposure to 12.5 μg organic-Hg from Thimerosal-
containing hepatitis B vaccines administered in the first
month of life in comparison to 0 μg organic-Hg from
Thimerosal-containing hepatitis B vaccines administered in
the first month of life among cases and controls revealed
similar risk of exposure (odds ratio = 1.03, p > 0.50). Simi-
larly, adverse event reports with the control outcome symp-
tom of febrile convulsion (VAERS code: 10016284) were
searched for in VAERS using the same methodology
employed for ASD. The results of that analysis failed to re-
veal a similar pattern of a significant association observed
for organic-Hg exposure from Thimerosal-containing DTaP
vaccine in comparison to Thimerosal-free DTaP vaccine
administration and the risk of reported ASD. There were
48 adverse event reports with febrile convulsions reported
to VAERS following administration of Thimerosal-
containing DTaP vaccines in comparison to 41 adverse
event reports with febrile conclusions reported to VAERS
following administration of Thimerosal-free DTaP vaccines
(risk ratio = 1.06, p > 0.50).
It is also possible that the VAERS and VSD databases ex-
amined in the present study may have limitations. As de-
scribed previously, VAERS may have shortcomings, such as
underreporting, difficulty in determining causal relation-
ship, lack of precise denominators. Nevertheless, as previ-
ously described by investigators from the CDC, almost all
of these types of shortcomings would apply equally to
VAERS reports after vaccines administered to similar popu-
lations [32], such as the Thimerosal-containing and
Thimerosal-free DTaP vaccines examined in the present
study. As a result, the comparison of vaccines administered
to similar populations should provide accurate relative
qualitative and quantitative relationships between vaccine
exposures and adverse outcomes [32]. The VSD may alsohave limitations because despite having vaccination and
medical records linked by computer, the cohort in VSD is
restricted to a limited population derived from several dif-
ferent participating HMOs. The validity of the databases
examined in the present study is significantly supported by
the consistency of the results observed in VAERS and VSD.
Another potential limitation of the present study is
that the results observed may be the result of statistical
chance. However, such a possibility would be unlikely
given the limited number of statistical tests performed,
the highly significant results observed (most p-values ob-
served were < 0.01), and the consistency in the direction
and magnitude of the results observed in two separate
epidemiological databases.
Still, other potential limitations of the present study
include the possibilities that some of the individuals in
the cohorts in VAERS and VSD examined may have had
more subtle neurological dysfunction that was not
brought to the attention of their healthcare providers,
healthcare providers may have misdiagnosed some indi-
viduals, or some vaccine exposures may not have been
appropriately classified. These limitations, while possibly
present in the data examined in the current study,
should not have significantly impacted the results ob-
served because it is unclear how differential application
would have occurred to the study cohorts examined
based upon the Thimerosal doses that the individuals re-
ceived. Moreover, misclassification occurring in the data
examined would tend to bias any results observed to-
ward the null hypothesis, since such effects would result
in individuals being placed in the wrong exposure and/
or outcome categories examined, and result in decreased
statistical power to determine true potential exposure-
outcome relationships.
In addition, another potential limitation of the present
study is that exposures to other sources of Hg were not
evaluated. It is very likely that the individuals examined
in the present study incurred other organic-Hg expo-
sures from other Thimerosal-containing childhood vac-
cines, dental amalgams, fish, or other environmental
sources. While these other sources of Hg may play a sig-
nificant involvement in the pathogenesis ASD, these un-
accounted for Hg exposures would actually tend to bias
the results observed towards the null hypothesis because
they potentially would confound the specific exposure
classifications of Hg examined. For example, individuals
classified as having lower organic-Hg exposure from
Thimerosal-containing vaccines may have actually re-
ceived high doses of Hg from other sources, and
individuals having higher organic-Hg exposure from
Thimerosal-containing vaccines may have actually re-
ceived low doses of Hg from other sources, with the net
result tending to minimize the magnitude of the associa-
tions observed.
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of the vaccines themselves or other components of the
vaccines studied, which in isolation or synergistically,
interacted with the organic-Hg exposures examined in
the present study. The former seems remote, since in
our study of DTaP vaccines in VAERS for example,
as summarized in Table 3, the composition of the
Thimerosal-free DTaP vaccine in comparison to the
Thimerosal-containing DTaP vaccine indicates that vac-
cine components such as antigens, aluminum, formal-
dehyde, and other trace constituents were more present
overall in the Thimerosal-free DTaP vaccine in compari-
son to the Thimerosal-containing DTaP vaccine. We
suggest that in future studies additional examination
should be undertaken further evaluate the potential ad-
verse consequences of the vaccines themselves or other
vaccine components both as a function of exposure and
timing of exposure.
Another limitation of the present study is that individuals
diagnosed with an ASD were based upon the information
contained in the automated adverse event reports reported
to VAERS or in the ICD-9 codes recorded within the auto-
mated medical records in VSD. As such, no additional
medical information was provided about the individuals ex-
amined, such as whether the individuals diagnosed with an
ASD experienced a regression. As discussed previously, it
would be important to examine such phenomena in future
studies, since regressive ASD would be expected to be as-
sociated with a neurological insult occurring in the early
postnatal period, whereas non-regressive ASD would be
expected to be more associated with a neurological insult
occurring in the prenatal period. It would be worthwhile
in future studies to attempt to further examine the poten-
tial relationship between timing of Hg exposure and the
initial onset of ASD symptoms.
Finally, the current study suffers from the potential













Trace constituents Formaldehyde, Geexplore the precise timing and cumulative doses of
organic-Hg from all Thimerosal-containing childhood
vaccines associated with maximum adverse conse-
quences. In future studies it would be worthwhile to fur-
ther explore these precise-timing and cumulative-doses
phenomena. In addition, it would be valuable to evaluate
other neurodevelopmental outcomes, as well as other
covariates such as gender, race, birth weight, etc., that
may further affect the magnitude of the adverse effects
found.Conclusion
The present study provides new epidemiological evidence
supporting an association between increasing organic-Hg
exposure from Thimerosal-containing childhood vaccines
and the subsequent risk of ASD diagnosis. Using a two-
phased, hypothesis-generating and hypothesis-testing, epi-
demiological analytical methodology in two separate data-
bases, organic-Hg exposure from Thimerosal-containing
childhood vaccines was determined to be associated with a
subsequent diagnosis of an ASD. In addition, in phase II
within the VSD, the present study placed special emphasis
on requiring an adequate follow-up period in the analysis.
Thus, the cases and controls were followed for a sufficient,
evidenced-based interval of time, to ensure that they were
appropriately classified with respect to their exposures and
outcomes, thus helping to ensure the potential for a cause-
and-effect relationship between exposure and outcome was
not biased or confounded. Future studies should be com-
pleted to further evaluate the relationship between other
sources of organic-Hg exposure from Thimerosal-
containing childhood vaccines and other chronic disorders,
and to further explore potential subpopulations and the
timing of exposure to organic-Hg from Thimerosal-
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is an important public health tool to reduce the morbid-
ity and mortality associated with infectious diseases.
However, it is also a public health imperative to end the
unnecessary addition of organic-Hg to vaccines in the
form of Thimerosal used as a preservative, based on data
showing an association between its administration and
adverse outcomes.
Abbreviations
(ACIP): Advisory Committee on Immunization Practices; (ASD): Autism
spectrum disorder; (BSS): Biologics surveillance summaries;
(DTaP): Diphtheria-Tetanus-acellular-Pertussis; (IRB): Institutional Review Board;
(KPC): Kaiser Permanente Colorado; (KPNW): Kaiser Permanente North-West;
(KPNC): Kaiser Permanente Northern California; (Hg): mercury; (NHIS): National
Health Interview Survey; (NIP): National Immunization Program; (CDC): US
Centers for Disease Control and Prevention; (FDA): US Food and Drug
Administration; (VAERS): Vaccine adverse event reporting system;
(VSD): Vaccine safety datalink.
Competing interests
All of the investigators on the present study have been involved in vaccine/
biologic litigation.
Authors’ contributions
DG was the main writer and analyzed data, BH was the main computer
programmer and reviewed the manuscript structure, ideas and science, JK
reviewed the manuscript structure, ideas and science, PG reviewed
manuscript structure, ideas, and science, LK edited manuscript structure, and
MG evaluated and reviewed manuscript ideas and science. All authors read
and approved the final manuscript.
Acknowledgements
This study was financially supported by the Dwoskin Family Foundation and
the Selz Foundation.
Author details
1The Institute of Chronic Illnesses Inc, 14 Redgate Ct, Silver Spring, MD, USA.
2Simpson University, Redding, CA, USA. 3University of Texas Southwestern
Medical Center at Dallas, Dallas, TX, USA. 4CoMeD Inc, Silver Spring, MD, USA.
Received: 12 October 2013 Accepted: 16 December 2013
Published: 19 December 2013
References
1. Boyle CA, Boulet S, Schieve LA, Cohen RA, Blumberg SJ, Yeargin-Allsopp M,
Visser S, Kogan MD: Trends in the prevalence of developmental disabil-
ities in US children, 1997–2008. Pediatrics 2011, 127:1034–1042.
2. Autism and Developmental Disabilities Monitoring Network Surveillance
Year 2008 Principal Investigators; Centers for Disease Control and
Prevention: Prevalence of autism spectrum disorders-Autism and Devel-
opmental Disabilities Monitoring Network, 14 sites, United States, 2008.
MMWR Surveill Summ 2012, 61:1–19.
3. Geier DA, Kern JK, Geier MR: A comparison of the Autism Treatment
Evaluation Checklist (ATEC) and the Childhood Autism Rating Scale
(CARS) for the quantitative evaluation of autism. J Ment Health Res
Intellect Disabil 2013, 6:255–267.
4. Geier DA, Kern JK, Geier MR: A prospective cross-sectional cohort assess-
ment of health, physical, and behavioral problems in autism spectrum
disorders. Maedica (Buchar) 2012, 7:193–200.
5. Kern JK, Geier DA, Sykes LK, Geier MR: Evidence of neurodegeneration in
autism spectrum disorder. Transl Neurodegener 2013, 2:17.
6. Desoto MC, Hitlan RT: Sorting out the spinning of autism: heavy metals
and the question of incidence. Acta Neurobiol Exp (Wars) 2010, 70:165–176.
7. Kern JK, Geier DA, Audhya T, King PG, Sykes LK, Geier MR: Evidence of
parallels between mercury intoxication and the brain pathology in
autism. Acta Neurobiol Exp (Wars) 2012, 72:113–153.
8. Geier DA, King PG, Sykes LK, Geier MR: A comprehensive review of
mercury provoked autism. Indian J Med Res 2008, 128:383–411.9. Kern JK, Haley BE, Geier DA, Sykes LK, King PG, Geier MR: Thimerosal
exposure and the role of sulfation chemistry and thiol availability in
autism. Int J Environ Res Public Health 2013, 10:3771–3800.
10. Ball LK, Ball R, Pratt RD: An assessment of Thimerosal use in childhood
vaccines. Pediatrics 2001, 107:1147–1154.
11. Singleton JA, Lloyd JC, Mootrey GT, Salive ME, Chen RT: An overview of the
vaccine adverse event reporting system (VAERS) as a surveillance
system. VAERS Working Group. Vaccine 1999, 17:2908–2917.
12. Geier DA, Geier MR: A review of the vaccine adverse event reporting
system database. Expert Opin Pharmacother 2004, 5:691–698.
13. Chen RT, DeStefano F, Davis RL, Jackson LA, Thompson RS, Mullooly JP,
Black SB, Shinefield HR, Vadheim CM, Ward JI, Marcy SM: The vaccine safety
datalink: immunization research in health maintenance organizations in
the USA. Bull World Health Organ 2000, 78:186–194.
14. Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS,
Mullooly JP, Black SB, Shinefield HR, Vadheim CM, March SM, Ward JI, Wise
RP, Wassilak SG, Hadler SC: Vaccine Safety Datalink project: a new tool for
improving vaccine safety monitoring in the United States. The Vaccine
Safety Datalink Team. Pediatrics 1997, 99:765–773.
15. Wassilak SG, Glasser JW, Chen RT, Hadler SC: Utility of large-linked data-
bases in vaccine safety, particularly in distinguishing independent and
synergistic effects. The Vaccine Safety Datalink Investigators. Ann N Y Acad
Sci 1995, 754:377–382.
16. Ellenberg SS, Braun MM: Monitoring the safety of vaccines: assessing the
risks. Drug Saf 2002, 25:145–152.
17. Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM, Chen RT:
Understanding vaccine safety information from the vaccine adverse
event reporting system. Pediatr Infect Dis J 2004, 23:287–294.
18. Iskander J, Pool V, Zhou W, English-Bullard R: VAERS Team. Data mining in
the US using the vaccine adverse event reporting system.
Drug Saf 2006, 29:375–384.
19. Pertussis vaccination: use of acellular pertussis vaccines among infants
and young children. Recommendations of the Advisory Committee on
Immunization Practices. MMWR Recomm Rep 1997, 46:1–25.
20. Hepatitis B virus: a comprehensive strategy for eliminating transmission
in the United States through universal childhood vaccination.
Recommendations of the Immunization Practices Advisory Committee
(ACIP). MMWR Recomm Rep 1991, 40:1–25.
21. Clarkson TW, Nordberg GF, Sager PR: Reproductive and developmental
toxicity of metals. Scan J Work Environ Health 1985, 11:145–154.
22. Burbacher TM, Shen DD, Liberato N, Grant KS, Cernichiari E, Clarkson T:
Comparison of blood and brain mercury levels in infant monkeys
exposed to methylmercury or vaccines containing Thimerosal.
Environ Health Perpsect 2005, 113:1015–1021.
23. Rodrigues JL, JM S i, Batista BL, Souza SS, Barbosa F Jr: Identification and
distribution of mercury species in rat tissues following administration of
Thimerosal or methylmercury. Arch Toxicol 2010, 84:891–896.
24. Zimmermann LT, Santos DB, Naime AA, Leal RB, Dorea JG, Barbosa F Jr, Aschner
M, Rocha JB, Farina M: Comparative study on methyl- and ethylmercury-
induced toxicity in C6 glioma cells and the potential role of LAT-1 in mediat-
ing mercurial-thiol complexes uptake. Neurotoxicology 2013, 38:1–8.
25. Geier DA, King PG, Geier MR: Mitochondrial dysfunction, impaired
oxidative-reduction activity, degeneration, and death in human neuronal
and fetal cells induced by low-level exposure to Thimerosal and other
metal compounds. Toxicol Environ Chem 2009, 91:735–749.
26. Young HA, Geier DA, Geier MR: Thimerosal exposure in infants and
neurodevelopmental disorders: an assessment of computerized
medical records in the Vaccine Safety Datalink. J Neurol Sci 2008,
271:110–118.
27. Gallagher CM, Goodman MS: Hepatitis B vaccination of male neonates
and autism diagnosis, NHIS 1997–2002. J Toxicol Environ Health A 2010,
73:1665–1677.
28. Geier DA, Geier MR: A meta-analysis epidemiological assessment of neu-
rodevelopmental disorders following vaccines administered from 1994
through 2000 in the United States. Neuro Endocrinol Lett 2006, 27:401–413.
29. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M: Association between
Thimerosal-containing vaccine and autism. JAMA 2003, 290:1763–1766.
30. Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B: Thimerosal
exposure in infants and developmental disorders: a retrospective cohort
study in the United Kingdom does not support a causal association.
Pediatrics 2004, 114:584–591.
Geier et al. Translational Neurodegeneration 2013, 2:25 Page 12 of 12
http://www.translationalneurodegeneration.com/content/2/1/2531. Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB,
Shinefield H, Chen RT: Vaccine safety datalink team. Safety of thimerosal-
containing vaccines: a two-phased study of computerized health main-
tance organization databases. Pediatrics 2003, 112:1039–1048.
32. Chen RT, Rosenthal S: An errant critique that misses the mark.
Arch Pediatr Adlesc Med 1996, 150:464–465.
doi:10.1186/2047-9158-2-25
Cite this article as: Geier et al.: A two-phase study evaluating the
relationship between Thimerosal-containing vaccine administration and the
risk for an autism spectrum disorder diagnosis in the United States.
Translational Neurodegeneration 2013 2:25.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
